Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504524 · ClinicalTrials.gov registry record
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
A clinical trial of Multiple Myeloma, sponsored by Pfizer.
- Completed
- Registry status
- 633
- Enrollment target
- 2
- Study locations
NCT06504524 is a study of Multiple Myeloma that has completed, run by Pfizer. The registered enrollment target is 633 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (16% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06504524, a study of Multiple Myeloma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 633 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). MM is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies. SOC are treatments that are accepted by medical experts as a proper treatment for a certain type of disease and that are widely used by doctors in real world. For people receiving elranatamab, the study doctors will use data from the other clinical trial (MagnetisMM-3). The study doctors will also use data from multiplemany real-world sources (TherapyMonitor MM Germany and Flatiron Health), for SOC in clinical practice. This study does not seek any participants for enrollment. The study doctors will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help the study doctors to know how well elranatamab can be used for RRMM treatment.
Conditions Studied
Interventions
- DRUG Standard of Care
- DRUG Elranatamab
Study Locations (2)
New York
- Pfizer - New York
Other
- Pfizer - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 633 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2024-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06504524
The ClinicalTrials.gov registry entry for NCT06504524 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 633 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (16% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT06504524 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Other.
Frequently Asked Questions
What is clinical trial NCT06504524 about?
NCT06504524 is a clinical study titled "A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US". The purpose of the study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). MM is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Sometimes MM might improve at first, but then gets resistant to th...
What is the current status of trial NCT06504524?
This trial is currently completed. The enrollment target is 633 participants. The study started on 2023-09-01. Estimated completion is 2024-05-31.
What conditions does trial NCT06504524 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06504524?
The interventions under investigation include: Standard of Care (DRUG), Elranatamab (DRUG).
Who is sponsoring clinical trial NCT06504524?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504524 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.